Wednesday January 16, 2019

Aspirin can restrict the growth of breast cancer, says Indian- origin researcher

0
//

download (4)

New York: A study led by an Indian-origin researcher has found a daily dose of aspirin is effective at blocking breast tumour growth in laboratory tests.

Aspirin is used worldwide as a ‘blood thinner’ and to relieve inflammation, pain and fever.

“The trick is to ensure conditions around cancer stem cells are not conducive for reproduction, something aspirin seems to be able to do,” said Sushanta Banerjee, professor at the University of Kansas Medical Centre in the US.

“We could give aspirin after chemotherapy to prevent relapse and keep the pressure on, which we saw was effective in both the laboratory and the mouse model, and we could use it preventatively,” Banerjee noted.

Experts suggest patients to consult with a doctor before starting a daily aspirin regimen. The drug is known to thin the blood and increase the risk of gastrointestinal bleeding.

“Of course there is a risk, but you have to weigh that against the risks of cancer,” Banerjee said.

To test his theory that aspirin could alter the molecular signature in breast cancer cells enough so that they would not spread, Banerjee used both incubated cells and mouse models.

For the cell test, breast cancer cells were placed in 96 separate plates and then incubated. Just over half the cultures were exposed to differing doses of acetylsalicylic acid, commonly known as aspirin.

According to Banerjee, exposure to aspirin dramatically increased the rate of cell death in the test. For those cells that did not die off, many were left unable to grow.

The second part of his study involved studying 20 mice with aggressive tumours.

For 15 days, half of the mice were given the human equivalent of 75 milligrams of aspirin per day, which is considered a low dose.

At the end of the study period, the tumours were weighed. Mice that received aspirin had tumours that were, on an average, 47 percent smaller.

To show that aspirin could also prevent cancer, the researchers gave an additional group of mice aspirin for 10 days before exposing them to cancer cells.

After 15 days, those mice had significantly less cancerous growth than the control group.

“We found aspirin caused these residual cancer cells to lose their self-renewal properties,” Banerjee said.

The study is to appear in the forthcoming issue of the journal Laboratory Investigation. (IANS)

Next Story

Drugs of Breast Cancer Useful in Treating Drug-Resistant Lung Tumours

For the study, the researchers targeted a specific interaction between the RAS protein and p110a

0
cancer
What is to be blamed for childhood cancer? Find it out here. Pixabay

A class of drugs used to treat certain breast cancer could help tackle lung cancers that have become resistant to targeted therapies, suggests a study done on mice.

The study showed that lung tumours in mice caused by mutations in a gene called EGFR shrunk significantly when a protein called p110a was blocked by the drugs.

“At the moment, patients with EGFR-mutant lung cancers are given targeted treatments that are very effective for the first few years,” said lead researcher Julian Downward, Associate Research Director of the Francis Crick Institute in the UK.

“These drugs are improving, but unfortunately after a couple of years, cancer usually becomes resistant and starts to grow and spread again. The second line of treatment is currently conventional chemotherapy, which is not targeted and has substantial side-effects,” said Downward.

Importantly, it would be worth investigating whether p110a inhibitors could be used as second-line therapy.

Cancer
Cancer Ribbon. Pixabay

Findings, published in Cell Reports, showed that when they blocked this interaction in genetically modified mice with EGFR mutations, their tumours shrank significantly to about a tenth of the space inside the lung.

Before the intervention, the tumours filled around two-thirds of the space inside the lung.

Also Read- Earthquake Measuring 6.1 Strikes Indonesia

These drugs could potentially benefit patients with EGFR-mutant lung cancers whose tumours have become resistant to treatment and could be approved for clinical purposes in the near future, the team suggested.

Since the research is at such an early stage, more research in mice and patient cells would be needed, Downward noted. (IANS)